A prosthetic heart valve can include an outer support assembly, an inner valve assembly, which define between them an annular space, and a pocket closure that bounds the annular space to form a pocket in which thrombus can be formed and retained. Alternatively, or additionally, the outer support assembly and the inner valve assembly can be coupled at the ventricle ends of the outer support assembly and the inner valve assembly, with the outer support assembly being relatively more compliant in hoop compression in a central, annulus portion than at the ventricle end, so that the prosthetic valve can seat securely in the annulus while imposing minimal loads on the inner valve assembly that could degrade the performance of the valve leaflets.

Endovascular systems for deployment at branched arteries include a main tubular graft body deployable within a main artery including a proximal end and an opposed distal end. The proximal and distal ends have a tubular graft wall therein between. A plurality of inflatable channels are disposed along the main tubular graft body, and at least one stent segment is disposed along the tubular graft wall of the main tubular graft body. The plurality of inflatable channels are configured to be inflatable with an inflation medium. The at least one stent segment is disposed between two or more adjacent inflatable channels of the plurality of inflatable channels.

Modular endoprosthesis for at least partial replacement of a tubular bone, comprising, as module components, a stem for insertion into a bone cavity of the tubular bone, and an end piece comprising a support body with a neck part arranged on the medial aspect thereof. Said module components being able to be coupled to each other and released from each other along a longitudinal axis of the shaft. The end piece has at least two different surface configurations on its support body, namely a closed surface (6′) on a medial aspect, and a porous configuration of the surface on the opposite, lateral aspect. The latter permits and positions the adhesion of muscle tissue, specifically without suturing. The muscle trauma caused by suturing, and the peak loads that occur at the respective suture points, can thus be avoided by virtue of the invention, by means of the location-specific direct adhesion of the muscle. It is thus possible to achieve quicker and reliable mobilization of the patient, and this with a reduced risk of complications.

A stent for insertion into a vessel of a patient includes an inner tube comprising a positive Poisson's ratio (PPR) material and defining a lumen extending along a longitudinal axis of the stent; and an outer tube comprising a negative Poisson's ratio (NPR) foam material and disposed around an entirety of the inner tube, the outer tube extending along the longitudinal axis of the stent. The stent is configured to exhibit an auxetic behavior in response to a deformation of the stent. An outer surface of the second portion is configured to apply a pressure to an inner surface of the vessel when the stent is implanted into the vessel and the deformation is removed.

A vascular stent (100) comprises a plurality of wave loops. In its natural state, in two of the wave loops which are adjacent in a group, a part of a wave crest of a lower layer wave loop are in a restrained connection with a part of a wave trough of an upper layer wave loop; the other part of the wave crest of the lower layer wave loop passes through the other part of the wave trough of the upper layer wave loop, and the other part of the wave crest and the other part of the wave trough are in a non-contact mutually-suspended connection. Some of the wave crests and wave troughs of the vascular stent (100) are in the non-contact mutually-suspended connection rather than the restrained connection, so that the maximum flexibility is provided to the stent, and meanwhile, the overall stability of the stent is guaranteed. The stent (100) can maintain a good shape during both implantation and the release process, so that safety during release is ensured.

The invention relates to a bone implant, comprising a main body, which has, in its outer region, an open-cell porous lattice structure, which is formed from a plurality of regularly arranged elementary cells, the elementary cells being in the form of an assembled structure and each being composed of an interior and of a plurality of interconnected bars surrounding the interior. The porous lattice structure is provided with a bone-growth-promoting coating comprising calcium phosphate, the calcium phosphate coating having a hydroxylapatite proportion forming a pore inner coating extending into the depth of the porous lattice structure.

A medical stent may include a tubular support structure including a plurality of struts defining a plurality of cells disposed between the plurality of struts. A polymeric coating may be disposed over the tubular support structure such that a first portion of the plurality of cells are closed by the polymeric coating in a first region of the tubular support structure and a second portion of the plurality of cells in a second region of the tubular support structure remain open to fluid flow and/or tissue ingrowth therethrough. The struts in the first region of the tubular support structure and the struts in the second region of the tubular support structure may be at least partially covered by the polymeric coating.

A prosthetic heart valve can include an outer support assembly, an inner valve assembly, which define between them an annular space, and a pocket closure that bounds the annular space to form a pocket in which thrombus can be formed and retained. Alternatively, or additionally, the outer support assembly and the inner valve assembly can be coupled at the ventricle ends of the outer support assembly and the inner valve assembly, with the outer support assembly being relatively more compliant in hoop compression in a central, annulus portion than at the ventricle end, so that the prosthetic valve can seat securely in the annulus while imposing minimal loads on the inner valve assembly that could degrade the performance of the valve leaflets.

An intravascular system having a first catheter having a first non-circular transverse cross-sectional configuration and a first delivery device configured for insertion into the lumen of the catheter. The first delivery device includes an implantable medical device and an elongated member supporting the first medical device such that the first elongated member and the first medical device are movable through the lumen of the first catheter. The first elongated member has a second non-circular transverse cross-sectional configuration corresponding to the first non-circular transverse cross-sectional configuration to thereby inhibit rotation of the first elongated member within the catheter and control orientation of the first medical device relative to the catheter.

The invention relates to a novel medical apparatus for treatment of obesity, diabetes, and/or other obesity-associated health problems. The apparatus is used to impede absorption of nutrients within the gastrointestinal tract, i.e., substantially isolating nutrients from a portion of the gastrointestinal tract. The apparatus can be implanted using minimally invasive techniques, such a transesophageal approach under visualization. More specifically, the apparatus is used to impede absorption of nutrients within the gastrointestinal tract, i.e., substantially isolating nutrients from a portion of the gastrointestinal tract. The apparatus may include a sleeve and at least one anchoring component attached to the sleeve with a releasable component. The sleeve may have different properties along its length or there may be multiple sleeves having different properties.